peptide garden
Menu
News

Correction: The Kennedy Peptide Reclassification Story

We could not verify the reported February 2026 HHS peptide reclassification against any primary source and removed the claim. Updated August 22, 2026: one of our own corrections was wrong — FDA did move twelve peptides out of Category 2 in April 2026, by nomination withdrawal rather than clearance.

·7 min read·RegulatoryCorrection

Update — August 22, 2026: one of our own corrections was wrong.

On August 15 we listed "FDA removed twelve peptides from Category 2 in April 2026" among the claims we could not verify. We have now verified it, and it is true. We checked FDA's page stamp but not the page itself, and a stamp is not a diff.

The correction is written out in full below, under What we got wrong about April 2026. Nothing about it makes any peptide legal to compound — but it is a real change to a real FDA list, and we told readers it had not happened.

Correction and re-review — August 15, 2026. This article was originally published in March 2026 and reported that HHS Secretary Robert F. Kennedy Jr. announced on February 27, 2026 that roughly 14 peptides would move from FDA's Category 2 list back to Category 1.

On re-review we could not verify that announcement against any primary source. The HHS press release we originally cited does not resolve, and the claim circulates almost entirely on low-quality commercial peptide sites. Several other citations in the original version could not be verified either. We have removed the unverifiable claims rather than leave them standing, and rewritten the page around what the public record actually shows.

We are keeping this page live, with this correction on it, because the claim is still widely repeated and readers deserve to find the correction where they find the claim.

What we can verify

Here is the documented record on peptides and 503A compounding, drawn from FDA's own publications and the Federal Register.

FDA maintains a statutory 503A Bulks List and a separate set of interim-policy categories. These are different things, and vendors conflate them constantly. The 503A Bulks List is established by rulemaking. The "Category 1 / 2 / 3" buckets come from FDA's interim policy on compounding with bulk drug substances and describe enforcement discretion, not statutory status.[1][5]

FDA continues to publish safety-risk findings for a number of nominated peptide bulk substances.[2]

On April 16, 2026, FDA published a Federal Register notice convening a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider seven peptide bulk drug substances for the 503A Bulks List, and opened public docket FDA-2025-N-6895.[6]

That meeting happened. The committee recommended six of the seven — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the list. Emideltide (DSIP) was voted down.[7]

FDA's own review team had recommended against all seven. Its slides state, for BPC-157: "FDA is proposing that BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List."[8]

FDA has taken no action since. As of August 22, 2026 there is no proposed rule, no Federal Register document, and no change to any bulks list. None of those six peptides is legal to compound today.

Quick facts

Feb 27, 2026 HHS announcement
Unverified — removed
April 16, 2026 FR notice
Verified (FR 2026-07361)
July 23-24, 2026 PCAC meeting
Verified — 6 of 7 recommended
FDA review team position
Against all seven
April 22, 2026 category 2 change
Verified — 12 peptides moved
FDA action since the vote
None as of Aug 22, 2026
Legal to compound today?
No

What we got wrong about April 2026

On April 22, 2026 — a week after the Federal Register notice that set the July PCAC meeting — FDA rebuilt its category 2 page. We missed it, then wrongly told readers it had not happened.

Here is the change, established by reading the live page against the Internet Archive's snapshot of the same URL from April 4, 2026.[3][4]

Before (stamped July 8, 2025) After (stamped April 22, 2026)
Substances in the category 2 table 26 14
"Nominated but withdrawn" table Did not exist 17 substances

Twelve peptides moved out of the category 2 table and into the new one: BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, Melanotan II, PEG-MGF, MOTS-c, semax, and TB-500.

FDA's heading for the new table says what happened: these substances "were withdrawn by the nominators." Nobody at FDA reviewed the safety evidence and cleared them. Whoever asked FDA to consider them stopped asking.

This does not make any of them compoundable, and the mechanism is worth understanding, because it is the opposite of what the marketing says.

A substance can be compounded under 503A only if it is on the 503A Bulks List. Category 2 was never the barrier — it was FDA's warning label while a nomination was pending. Withdrawing the nomination removes the pending question. It does not answer it.

So a peptide that leaves category 2 by withdrawal ends up further from a legal pathway, not closer: there is no longer even an application in front of FDA. And FDA kept publishing its safety-risk finding for all twelve on the very same page.

Two peptides are still in the active category 2 table: ipamorelin acetate (503B, added September 29, 2023) and kisspeptin-10 (503A, added September 29, 2023). Ipamorelin appears in both tables at once, because its 503A nomination was withdrawn while its 503B placement stands. If you see "ipamorelin was removed from Category 2," that is the half of the story that is true.

Note the overlap with the July meeting. Six of the twelve withdrawn peptides — BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon — were on the July 23-24 PCAC agenda and were recommended for the 503A Bulks List three months later. The withdrawal and the re-nomination are separate events involving the same molecules, which is a large part of why coverage of this has been so confused.

Why we are not repeating the reclassification story

A few things we specifically could not confirm, and therefore will not publish:

  • Any HHS or Secretary-level statement in the relevant windows that roughly 14 of 19 Category 2 peptides would be returned to Category 1.
  • That FDA signalled it would "soon remove" the peptides under review from any restricted list. The April 2026 Federal Register notice is a meeting notice; it does not say that.[6]

We are not saying these things definitely did not happen. We are saying we could not find a primary source for them, and a peptide encyclopedia that cites press releases it cannot open is not worth reading. If FDA or HHS publishes documentation, we will update this page.

What this means for you

The practical status has not changed. BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and DSIP are not on the 503A Bulks List. A licensed compounding pharmacy cannot legally prepare them from bulk today.

Watch the Federal Register, not press coverage. The only thing that will change the legal status of these peptides is a proposed rule followed by a final rule. Both appear in the Federal Register. Nothing else — not an advisory vote, not a press statement, not a vendor's blog post — has that effect.

Be skeptical of "peptides are legal again" marketing. The four steps matter: committee recommended is not FDA proposed, which is not FDA finalized, which is not legal to compound. Sellers have a commercial reason to blur them.

For the full record of the July meeting, see our July 2026 PCAC hub. For source-checked status on every peptide we track, see the legal status tracker.

References

  1. [1]
    U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” FDA.gov. 2026. LinkRegulatory document

    FDA's page defining the 503A Bulks List and the interim-policy categories. Checked August 15, 2026; FDA's own 'content current as of' stamp was May 14, 2026.

  2. [2]
    U.S. Food and Drug Administration. “Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding.” FDA.gov. 2026. LinkRegulatory document

    FDA's enumeration of nominated bulk substances it has identified as presenting significant safety risks. Checked August 15, 2026; FDA-stamped current as of April 22, 2026.

  3. [3]
    U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” FDA.gov. 2026. LinkRegulatory document

    The live FDA page, re-read line by line on August 22, 2026. FDA-stamped content current as of April 22, 2026. Carries two tables: 'Bulk drug substances under category 2 of the interim policies' (14 substances) and 'Bulk drug substances nominated but withdrawn' (17 substances).

  4. [4]
    U.S. Food and Drug Administration (archived by the Internet Archive). “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — snapshot of April 4, 2026.” Internet Archive Wayback Machine. 2026. LinkRegulatory document

    The same FDA page eighteen days earlier, stamped content current as of July 8, 2025. Its category 2 table holds 26 substances and contains no 'nominated but withdrawn' section. Comparing this snapshot against the live page is what let us date and enumerate the change.

  5. [5]
    U.S. Food and Drug Administration. “Compounding Laws and Policies: Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.” FDA.gov. 2026. LinkRegulatory guidance
  6. [6]
    U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Federal Register. 2026. LinkFederal Register notice

    FR Doc. 2026-07361, published April 16, 2026. Establishes the July 23-24, 2026 PCAC meeting and public docket FDA-2025-N-6895.

  7. [7]
    U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” FDA.gov. 2026. LinkRegulatory document
  8. [8]
    U.S. Food and Drug Administration. “July 23, 2026 PCAC Meeting — FDA Presentations.” FDA.gov. 2026. LinkRegulatory document

    FDA's own slide deck, in which its review team proposes that none of the seven peptides be added to the 503A Bulks List.

The regulatory landscape is moving fast

Get notified when new regulatory changes affect peptide access. We track the FDA, so you don't have to.

Related content

Guide

The July 2026 PCAC Peptide Vote

What the advisory committee actually decided, what FDA's reviewers argued, and what has to happen next.

Tool

Peptide Legal Status Tracker

Source-checked status for every peptide we track, updated August 15, 2026.

News

Does This Mean BPC-157 Is Legal Now?

The precise answer to the question the July vote made everyone ask.

News

FDA Peptide Categories Explained

How the interim-policy categories differ from the statutory 503A Bulks List.

Guide

Our Methodology

How we grade evidence, what we cite, and what we do when a source does not hold up.

Disclaimer

Peptide Garden is an educational resource, not a medical provider. This article was originally published March 1, 2026 and was substantially corrected on August 15, 2026 after a source review found the central claim unverifiable. Nothing in this article constitutes medical advice, legal advice, or a recommendation to use any peptide therapy. Always consult a licensed healthcare provider before making decisions about peptide use, and verify current regulatory status through official FDA channels.